Adalta Ltd. · ASX:1AD
Adalta — ShareCafe Small Cap "Hidden Gems" Webinar (January 2022)
16 slides from Adalta's conference presentation, Jan 20, 2022
Slide 1: ASX Announcement: AdAlta updated corporate presentation and investor webinar
20 January 2022 ASX Announcement ADALTA UPDATED CORPORATE PRESENTATION AND INVESTOR WEBINAR For personal use only MELBOURNE Australia, 20 January 2022: AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform is pleased to anno
Slide 2: About AdAlta, i-bodies and AD-214
AdAlta is also entering collaborative partnerships to co-develop i-body enabled therapeutics. The Company has a revenue generating partnership agreement with GE Healthcare which is designed to discover a diagnostic imaging agent for use in immuno- oncology. For personal use only AdAlta’s growth stra
Slide 3: Corporate overview
For personal use only Corporate overview January 2022
Slide 4: AdAlta today
INVESTOR PRESENTATION – JANUARY 2022 AdAlta today For personal use only AdAlta is building significant growth momentum while retaining agility to respond and adapt to data and opportunities • i-body platform: can create therapeutics addressing targets underserved by traditional antibodies • Fibrosis
Slide 5: Four human health needs AdAlta is addressing today
INVESTOR PRESENTATION – JANUARY 2022 Four human health needs AdAlta is addressing today For personal use only Antibodies cannot do everything! - Focus today AdAlta’s i-bodies are a new drug discovery platforms for challenging targets Idiopathic Pulmonary Fibrosis: degenerative, fatal AdAlta’s AD-214
Slide 6: For personal use only
$+()%'&'($)) %$F !$*'- "#$##$"$$ "" ## For personal use only *$ %!&$$ 2:;<27,5*;;56<-346,- =6*7 6.)+:165:8-):4-5: =70 %2;;=. &)8/-:9)8-+-7:68+)33-, (# !684)3 19-)9-, 51:1)3.6+;919-289*<12, !=5687*:A2+:8;2; !65-6.)/86;7 8=;. 6. 7<.:;<2<2*5=70 68-.58/ 2;.*;.; ; 5=70 /2+:8;2; 58,4270(# :.-=,.;/2+:8;2;1
Slide 7: Idiopathic Pulmonary Fibrosis (IPF)
INVESTOR PRESENTATION – JANUARY 2022 Idiopathic Pulmonary Fibrosis (IPF) For personal use only AdAlta’s first target, already a $3b market, is a degenerative, fatal disease in dire need of improved treatment options: i-bodies have been designed to target a novel mode of action to address this medica
Slide 8: Phase I clinical and PET imaging inform dosing and route of administration
JA INVESTOR PRESENTATION – JANUARY 2022 Phase I clinical and PET imaging inform dosing and route of administration For personal use only Intravenous AD-214 is well tolerated in Phase I studies; PET imaging with radiolabelled AD-214 supports early transition to inhaled route of administration Phase I
Slide 9: Predicted regional deposition of AD-214 in human lungs
INVESTOR PRESENTATION – JANUARY 2022 Predicted regional deposition of AD-214 in human lungs For personal use only The ICRP661 model predicts that 17-46% of AD-214 delivered from commercial nebulisers will be delivered to the smallest (alveolar/interstitial) airways of the lungs where most IPF is fou
Slide 10: AD-214: multiple indication extension options
INVESTOR PRESENTATION – JANUARY 2022 AD-214: multiple indication extension options For personal use only Each additional indication could address multiple markets with US$ billion potential Data in tissue and animal models show that AD-214 may improve fibrosis across a range of fibrotic diseases and
Slide 11: CAR-T therapies are revolutionising cancer treatment
INVESTOR PRESENTATION – JANUARY 2022 CAR-T therapies are revolutionising cancer treatment For personal use only Reprogramming a patient’s own immune system to fight cancer is a fast-growing market at the cutting edge of medicine earned by CAR-T therapy 0 step 1 CAR engineered chem okine >US$1b produ
Slide 12: Building the first iCAR-T cell therapy: proof of principle results
INVESTOR PRESENTATION – JANUARY 2022 Building the first iCAR-T cell therapy: proof of principle results For personal use only i-body enabled CAR-T (iCAR-T) cells have been successfully generated by Carina and demonstrate in vitro cell killing (lysis)1 ~ ') JA tsI~Jtg biorech 1%15 un 10 100 100 □ UT
Slide 13: Calendar 2022 goals
INVESTOR PRESENTATION – JANUARY 2022 Calendar 2022 goals For personal use only Significant progress anticipated on both existing core programs and further pipeline expansion AD-214 – first in class anti-fibrotic • Inhaled formulation development: nebulisation feasibility, efficacy in animal model of
Slide 14: Corporate snapshot
INVESTOR PRESENTATION – JANUARY 2022 Corporate snapshot For personal use only Key financial details (22 Dec 2021) Share price performance (last 12 months) ASX code 1AD 0.25 7.0 Market capitalisation A$24.32m 6.0 0.20 Share price (12 month closing range) A$0.082 ($0.074 - 0.195) 5.0 12 month return (
Slide 15: Investment proposition
INVESTOR PRESENTATION – JANUARY 2022 Investment proposition For personal use only • Fibrosis/inflammation Lead asset advancing to Phase II Immuno-oncology 2 x co-development collaborations to leverage platform i-body platform to create value >$3b market potential in first indication1 ü GE Healthcare
Slide 16: Contact
For personal use only Contact: Tim Oldham, CEO and Managing Director [email protected] www.adalta.com.au
AdAlta — ShareCafe Small Cap "Hidden Gems" Webinar (January 2022) on 6ix